Please select the option that best describes you:
Topics:
Internal Medicine • COVID-19 • Infectious Disease • Pulmonology • Pulmonary Infections • General Infectious Disease
Do you consider the use of tocilizumab in patients with COVID pneumonia who have had an improvement in supplemental O2 requirements but have significantly elevated inflammatory markers after day two of remdesivir and dexamethasone?
Answer from: at Academic Institution
I don’t use tocilizumab if the clinical condition is improving.
Sign in or Register to read more